CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

Biotechnology leader CSL Behring announced its Biologics License Application (BLA) for etranacogene dezaparvovec, an investigational treatment for hemophilia B, has been accepted by the U.S. Food and Drug Administration for priority review. If approved, it would be the first gene therapy treatment for hemophilia B.